[go: up one dir, main page]

ZA98367B - Antibodies which bind to the nidogen-binding domain of laminin their preparation and use - Google Patents

Antibodies which bind to the nidogen-binding domain of laminin their preparation and use

Info

Publication number
ZA98367B
ZA98367B ZA98367A ZA98367A ZA98367B ZA 98367 B ZA98367 B ZA 98367B ZA 98367 A ZA98367 A ZA 98367A ZA 98367 A ZA98367 A ZA 98367A ZA 98367 B ZA98367 B ZA 98367B
Authority
ZA
South Africa
Prior art keywords
nidogen
laminin
antibodies
bind
preparation
Prior art date
Application number
ZA98367A
Other languages
English (en)
Inventor
Martin Gerl
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of ZA98367B publication Critical patent/ZA98367B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA98367A 1997-01-17 1998-01-16 Antibodies which bind to the nidogen-binding domain of laminin their preparation and use ZA98367B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19701607A DE19701607A1 (de) 1997-01-17 1997-01-17 Anitkörper, die an die Nidogen-Bindungsdomäne des Laminins binden, deren Herstellung und Verwendung

Publications (1)

Publication Number Publication Date
ZA98367B true ZA98367B (en) 1998-07-17

Family

ID=7817701

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA98367A ZA98367B (en) 1997-01-17 1998-01-16 Antibodies which bind to the nidogen-binding domain of laminin their preparation and use

Country Status (18)

Country Link
US (1) US20010007020A1 (cs)
EP (1) EP0954535A1 (cs)
JP (1) JP2001509020A (cs)
KR (1) KR20000070256A (cs)
CN (1) CN1244873A (cs)
AR (1) AR011074A1 (cs)
AU (1) AU5985398A (cs)
BR (1) BR9714207A (cs)
CA (1) CA2278477A1 (cs)
CZ (1) CZ253899A3 (cs)
DE (1) DE19701607A1 (cs)
HU (1) HUP0001808A3 (cs)
ID (1) ID21895A (cs)
IL (1) IL130808A0 (cs)
PL (1) PL334956A1 (cs)
TR (1) TR199901648T2 (cs)
WO (1) WO1998031709A1 (cs)
ZA (1) ZA98367B (cs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087318A1 (en) * 1994-04-18 2003-05-08 Lallone Roger L. Antibodies against an extracellular matrix complex and their use in the detection of cancer
EP1070727A1 (en) 1999-03-01 2001-01-24 Aventis Pharma Deutschland GmbH Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction
JP2003525595A (ja) * 1999-11-01 2003-09-02 キュラゲン コーポレイション 脈管形成に含まれる差動発現遺伝子、それにコードされるポリペプチド、及びそれを用いた方法
AU2001237068A1 (en) * 2000-02-18 2001-08-27 Jagat Narula Detection of microbial deposition and immune response at the basement membrane
US20030119739A1 (en) * 2000-03-29 2003-06-26 Beth Israel Deaconess Medical Center Anti-angiogenic and anti-tumor properties of Vascostatin and other nidogen domains
WO2001073033A2 (en) * 2000-03-29 2001-10-04 Beth Israel Deaconess Medical Center, Inc. Anti-angiogenic and anti-tumor properties of matin and other laminin domains
WO2004093892A2 (en) 2003-04-16 2004-11-04 Genentech, Inc. Stanniocalcin-1, variant or antagonists thereof for selective modulation of vascularization
US20140045196A1 (en) * 2012-08-13 2014-02-13 University Of Tokyo Methods of prognosis and diagnosis of cancer
CN110860766A (zh) * 2019-10-22 2020-03-06 广东开放大学（广东理工职业学院） 铝合金薄板的调制脉冲电流焊接方法、系统及存储介质

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211657A (en) * 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
EP0696597B1 (de) * 1994-08-11 2008-03-26 Sanofi-Aventis Deutschland GmbH Monoklonale Antikörper zur selektiven immunologischen Bestimmung von hochmolekularen, intakten Lamininformen in Körperflüssigkeiten
US5493008A (en) * 1994-08-15 1996-02-20 The University Of Virginia Patent Foundation Two non-contiguous regions contribute to nidogen binding to a single EGF-like motif of the laminin γ1 chain

Also Published As

Publication number Publication date
AR011074A1 (es) 2000-08-02
IL130808A0 (en) 2001-01-28
ID21895A (id) 1999-08-05
EP0954535A1 (de) 1999-11-10
WO1998031709A1 (de) 1998-07-23
KR20000070256A (ko) 2000-11-25
CN1244873A (zh) 2000-02-16
PL334956A1 (en) 2000-03-27
BR9714207A (pt) 2000-03-28
DE19701607A1 (de) 1998-07-23
HUP0001808A3 (en) 2001-09-28
AU5985398A (en) 1998-08-07
CZ253899A3 (cs) 1999-10-13
CA2278477A1 (en) 1998-07-23
JP2001509020A (ja) 2001-07-10
HUP0001808A2 (hu) 2000-09-28
US20010007020A1 (en) 2001-07-05
TR199901648T2 (xx) 1999-10-21

Similar Documents

Publication Publication Date Title
HUP1500179A2 (en) The use of human tnf-alpha binding antibodies
IL144578A0 (en) Antibodies specific to kdr and uses thereof
ID26590A (id) Komposisi-komposisi dua fasa bebas pewangi dan metode-metode untuk menurunkan bau badan dan lingkungan
FI963126L (fi) Stanoliseos ja sen käyttö
ID21859A (id) Bahan lembaran serupa-kulit dan metode untuk memproduksi bahan tersebut
IL136335A0 (en) Monoclonal human natural antibodies
IL136113A0 (en) Modified antibodies with enhanced ability to elicit an anti-idiotype response
HUP0400697A3 (en) Silensed anti-cd28 antibodies and use thereof
AU6949800A (en) Compositions and methods for the treatment of sepsis using antibodies to c5a
GB2327190B (en) Process for the preparation of depilatory compositions and their use
HUP0101151A3 (en) Monoclonal antibody anti alphav-integrin and its use to inhibit alphavbetha6-integrin attachment to fibnronectin
EG21286A (en) Blends of organosillane compounds and their use
ZA98367B (en) Antibodies which bind to the nidogen-binding domain of laminin their preparation and use
ZA985457B (en) Isolated nona- and decapeptides which bind to HLA molecules and the use thereof
NZ298241A (en) Preparation of intermediates in the synthesis of cephalosporins
FI964854A7 (fi) Hydroksitioasetamidien valmistus ja niiden käyttö bentsotiofeenien syn teesissä
EP0934063A4 (en) USE OF SIALIDASE ANTIBODIES AS ANTI-INFECTIOUS AND ANTI-INFLAMMATORY AGENTS
EP1070081A4 (en) NEW PROTEINS OF THE FAMILY OF PROTEINS T129 AND USES THEREOF
FR2747308B1 (fr) Association de margousier, de (-) hydroxycitrate et de ceramides et compositions les renfermant
GB9828185D0 (en) Preparation of antibodies
GB9516606D0 (en) Antibodies their preparation and use
GB2371049B (en) Methods of making antibodies against ß-forms of prion proteins and their uses
GB9823937D0 (en) Therapeutic antibody composition and use
GB9823942D0 (en) Therapeutic antibody composition and use
GB9823939D0 (en) Therapeutic antibody composition and use